Mr. Andrew Alvis reports
ISODIOL INTERNATIONAL INC. ANNOUNCES DELAY IN FILING ANNUAL FINANCIAL STATEMENTS
Due to circumstances created by the COVID-19 global pandemic, Isodiol International Inc. will not be filing its audited financial statements, related management's discussion and analysis, and certifications of the financial statements for the fiscal year ended March 31, 2020, by the scheduled due date of July 29, 2020, as required under Section 4.2(b) and Section 5.1(1) of National Instrument 51-102 (Continuous Disclosure Obligations). Isodiol International, Inc. will also not be filing its June 30, 2020, quarterly report and management discussion and analysis by the scheduled due date of August 31, 2020.
On May 20, 2020, the Canadian Securities Administrators ("
") issued a notice stating that securities regulators will be providing coordinated relief consisting of a 45-day extension for certain periodic filings required to be made between June 2, 2020 and August 31, 2020, as a result of the COVID-19 pandemic. As such the British Columbia Securities Commission ("
") has enacted Instrument 51-517 -
Temporary Exemption from Certain Corporate Finance Requirements with Deadlines during the Period from June 2 to August 31, 2020
BC Instrument 51-517
"). The Company will be relying on this extension period due to delays experienced as result of the COVID-19 pandemic.
As required by BCSC Instrument 51-517, and similar orders in the Company's other reporting jurisdictions, the Company discloses the following:
- The Company expects to file its audited financial statements, related management discussion and analysis and certifications of financial statements for the fiscal year ended March 31, 2020 on or about September 14, 2020, and the quarterly report, related management discussion and analysis and certifications on or about October 15, 2020; and
- In the interim, the Company's management and other insiders will be subject to a trading black-out policy that reflects the principles in Section 9 of National Policy 11-207 -
Failure-to-File Cease Trade
The Company confirms that since the filing of its financial statements and related management discussion and analysis for the period ended December 31
, 2019, there have been no material business developments other than those disclosed through news releases.
Andrew S. Alvis Marcos Agramont
President and Director, CEO and Director
Isodiol International, Inc. Isodiol International, Inc.
Follow our Corporate updates on Facebook
About Isodiol International Inc.
Isodiol International Inc.
is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based Consumer Packaged Goods (CPG) and solutions. Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.